DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

20061,723 citationsJournal Articlebronze Open Access

Authors

Ken A. Olaussen · Commissariat à l'Énergie Atomique et aux Énergies Alternatives

Ariane Dunant · Institut Gustave Roussy

Pierre Fouret · Sorbonne Université

Élisabeth Brambilla · Centre Hospitalier Universitaire de Grenoble

Fabrice André · Institut Gustave Roussy

Vincent Haddad · Institut Gustave Roussy

E. Taranchon

Abstract

Patients with completely resected non-small-cell lung cancer and ERCC1-negative tumors appear to benefit from adjuvant cisplatin-based chemotherapy, whereas patients with ERCC1-positive tumors do not.

Topics & Keywords

Cancer Genomics and Diagnostics DNA Repair Mechanisms Genetic factors in colorectal cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 355, Issue 10, pp. 983-991

DOI: 10.1056/nejmoa060570

Field-Weighted Citation Impact: 54.45